MichaelDavidRosenblumMD
Dermatology • San Francisco, CAAssistant Professor in Residence, Dermatology, UCSF School of Medicine
Are you Dr. Rosenblum?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 32 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1701 Divisadero St
Fl 3
San Francisco, CA 94115Phone+1 415-353-7800
Summary
- Dr. Michael Rosenblum, MD is a board certified dermatologist in San Francisco, California. He is currently licensed to practice medicine in California. He is affiliated with UCSF Medical Center and is an Assistant Professor in Residence at UCSF School of Medicine.
Education & Training
University of California (San Francisco)Residency, Dermatology, 2007 - 2010
Aurora Health CareInternship, Transitional Year, 2006 - 2007
Medical College of WisconsinClass of 2006
Certifications & Licensure
CA State Medical License 2007 - 2025- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FAAD) American Academy of Dermatology
Publications & Presentations
PubMed
- CD4T Cells Occupy Perivascular and Perifollicular Niches in Healthy Human Skin.Courtney E Macon, Annie Yang, Dhara Patel, Jeffrey P North, Michael D Rosenblum
Experimental Dermatology. 2024-12-01 - Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.Zoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, Chaorong Wu, Clinton Wu
BJC Reports. 2024-06-24 - 2 citationsInterleukin-2-induced skin inflammation.Charline Sommer, Jarish N Cohen, Susann Dehmel, Vanessa Neuhaus, Dirk Schaudien
European Journal of Immunology. 2024-04-01
Press Mentions
UCSF Dermatologist Enlists Help of Rock Stars for Debut Solo AlbumNovember 4th, 2024- TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the Treatment of Cancer and Inflammatory DiseasesJune 22nd, 2021
- TRexBio Chomps down on $59 Million Series A for ImmunobiologyJune 22nd, 2021
- Join now to see all
Professional Memberships
- Fellow
